Coeptis Therapeutics Inc (COEP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.54 (+10.92%), Market cap $0.10B, 52-week low–high $7.05 ~ $18.80.
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid
Financial statements, price targets, institutional (13F) holdings and related news for Coeptis Therapeutics Inc are updated in real time on BlackAll Trade.
Coeptis Therapeutics Inc trades at $2.54 (+10.92%). Real-time quotes and charts are available on BlackAll Trade.
Coeptis Therapeutics Inc has a market cap of about $0.10B.
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates